Mymetics Corporation Hires the Investor Relations Group

Mymetics Corporation (OTCBB: MYMX; http://www.mymetics.com), a biotechnology company focused on the development of protective mucosal antibody-based vaccines, hired the Investor Relations Group (“IRG”), a corporate communications firm based in New York City, to serve as its investor relations and financial public relations firm.

IRG’s investor relations team will implement competitive analysis strategies and its proprietary database of portfolio managers and equity analysts in the healthcare investment community to increase awareness of the Company’s protective mucosal antibody-based vaccine platform using virosomes© — a biosynthetic vesicle representing reconstituted empty influenza virus envelopes — as its approach against human immunodeficiency syndrome (HIV), malaria and other empirically similar retroviruses. The program will include pre-qualified one-on-one introductions, traditional outreach practices and strategic advisement.

The public relations team will initiate an outreach campaign to the media-at-large, namely editors, writers and producers of local and national trade, consumer print and broadcast outlets.

“As our vaccine gains acceptance in the European Community and across the globe, we have a responsibility to make our research known amongst the investment community as well as around the world,” said Christian J. F. Rochet, CEO and president of Mymetics Corporation. “We feel confident in IRG’s ability in assisting us in this task.”

About Mymetics Corporation

Mymetics is a biotechnology company developing prophylactic vaccines that combine innovative antigen engineering, minimal human protein homologies, and virosome technology. Mymetics’ vaccine approach is focused on eliciting immune protection capable of interfering with late events of pathogen transmission, coupled, most importantly, with early events of pathogen transmission, such as preventing the entry across the mucosal tissues that are very often the primary entry door of most of the pathogens. Virosomes are biosynthetic vesicles representing reconstituted empty influenza virus envelopes that serve as a highly efficient vaccine delivery system with intrinsic adjuvant potential. The Company’s disease focus presently includes malaria and the human immunodeficiency virus (HIV).

For further information regarding the Company and its mucosal approach, please visit www.mymetics.com.

Safe Harbor Forward-Looking Statements

Statements contained in this release that are not strictly historical are “forward-looking statements.” Such forward-looking statements are sometimes identified by words such as “intends,”"anticipates,”"believes,”"expects” and “hopes.” The forward-looking statements are made based on information available as of the date hereof, and the Company assumes no obligation to update such forward-looking statements. Editors and investors are cautioned that such forward-looking statements involve risks and uncertainties that could cause the Company’s actual results to differ materially from those in these forward-looking statements. Such risks and uncertainties include but are not limited to demand for the Company’s products and services, our ability to continue to develop markets, general economic conditions, our ability to secure additional financing for the Company and other factors that may be more fully described in reports to shareholders and periodic filings with the Securities and Exchange Commission.